AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02697305 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: IV BCAA
Description: in total dose of 0,4 g/kg in a 2 h intravenous infusion
Study NCT02697305 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ORAL BCAA
Description: single dose of 0.4g/kg administered over 30s washed down with 500mL of tap water
Study NCT02697305 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: ORAL Placebo
Description: single dose of 0.4 g/kg administered over 30 s washed down with 500mL of tap water
Study NCT00918203 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Olaratumab
Description: 15 mg/kg of olaratumab on Days 1 and 8 of each 21-day cycle, administered intravenously (IV) at 25 milligram/minute (mg/min), with a minimum infusion time of 30 minutes.
Study NCT00918203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 200 mg/m2 is then administered IV over 3 hours
Study NCT00918203 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 200 mg/m2 is then administered IV over 3 hours
Study NCT00918203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC=6 administered IV over 30 minutes on Day 1 of each 3-week cycle for a maximum of six cycles. Once the maximum of 6 cycles of carboplatin are reached the participant may continue on olaratumab maintenance for up to 12 months.
Study NCT00918203 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: AUC=6 administered IV over 30 minutes on Day 1 of each 3-week cycle for a maximum of six cycles. Once the maximum of 6 cycles of carboplatin are reached the participant may continue on olaratumab maintenance for up to 12 months.
Study NCT02644369 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
Study NCT05119543 — intervention group
Intervention type: OTHER
Intervention: outdoor time
Description: This cohort study aimed to assess the change of refractive status in Chinese school children under different outdoor time
Study NCT00781118 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Guardian System
Description: There is no intervention in this study. The device is a diagnostic only.
Study NCT00781118 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Guardian System
Description: There is no intervention in this study. The device is a diagnostic only.
Study NCT00354237 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Conventional antidiabetic treatment
Description: No intensive treatment
Study NCT00354237 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive insulin treatment
Description: Intensive insulin treatment
Study NCT03919110 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Collection of biological samples
Description: Investigators are building a collection of biological samples to perform biological assays and multiple analyses so-called omics: genomics (on the entire genome), proteomics (on all proteins) etc...This will make it possible to identify the genetic mutations or biological markers present or absent in these diseases, making it possible to confirm a diagnosis or to eliminate differential diagnoses.
Study NCT03492866 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gentamicin Sulfate
Description: Topical treatment of 1 side of the scalp twice daily during 6 months
Study NCT03657316 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nutrition education
Description: The content of the three days workshop:Healthy diet, Diet-related health risks and diseases, Physical activity The sustained multi-component program will be based on The three days nutritional and physical education workshop Enhanced physical education Involvement of the morning broadcast in provision of messages for students about nutrition and physical activity Brochure including key messages about diet and physical activity will be designed and sent to parents of the intervention classes of students A monthly telephone call or a text message will be sent to the parents to remind them about the commitment to the dietary health practices.~Message to school administration to prevent selling of soft drinks and to sell healthy food A monthly session for three months will be held to remind the students with the messages
Study NCT01155206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glucagon
Description: glucagon 3ng/kg/min
Study NCT00258830 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone®: Influenza Virus Vaccine
Description: 0.5 mL, Intramuscular
Study NCT03615352 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ovarian cystectomy
Description: laparoscopic ovarian cystectomy in endometrioma
Study NCT03615352 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ovarian cyst aspiration and coagulation
Description: laparoscopic ovarian cyst aspiration and coagulation in endometrioma
Study NCT03558269 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autlogous UCB infusion
Description: Infants delivered with hypoplastic left heart syndrome and transposition of great arteries undergoing surgery in the 1st 2 weeks of life will be treated with autologous UCB after the surgery. Each group will be followed by MRI before (1-3 days) and after the surgery between at 10 POD. Developmental follow up will be done at 1, 6 and 12 months. Another brain MRI will be done at 6 months of age.
Study NCT03943940 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Standard medicine
Study NCT00566332 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorambucil
Description: Chlorambucil 8 mg/m² (6 mg/m² if patient aged more than 75 years old) 10 days every 28 days during 12 months By oral route
Study NCT00566332 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine
Description: Fludarabine 40 mg/m² (30 mg/m² if patient aged more than 75 years old) 5 days every 28 days during 6 cycles By oral route
Study NCT04780191 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MyoRegulator®
Description: Trans-spinal DC stimulation paired with peripheral DC stimulation
Study NCT04780191 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: MyoRegulator®
Description: Trans-spinal DC stimulation paired with peripheral DC stimulation
Study NCT01884155 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic umbilical cord blood therapy
Study NCT02331706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon alpha-2B (IFN-α) 3 million units (MU) subcutaneous daily
Study NCT03630185 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Custom-manufactured compression hosiery (Isobar)
Description: The custom-fitted garment is manufactured specifically for each patient based on measurements taken with a 3-dimensional volumetric laser scan of the extremity, and can be sized individually to each limb.
Study NCT03630185 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Off-the-rack stockings (Sigvaris)
Description: Currently available off-the-rack compression hosiery are manufactured in eight fixed sizes (S-XLFC) that cannot be varied in size over their length to accommodate unusual anatomic patterns (eg., small ankle with large calf or vice versa) and may not achieve a comfortable fit that meets the compression goal over a uniform distribution of the limb.
Study NCT01688427 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard IPV Assessment
Description: Test the effectiveness of the eMOCHA DOVE application using mHealth technology for routine assessment of IPV vs. Pencil and paper at enrollment, delivery, and 2 months post birth.
Study NCT01688427 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard DOVE Intervention
Description: Intervention will be administered via eMOCHA tablet vs. home visitor over 6 sessions in 6 months.
Study NCT00032110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given orally
Study NCT01414855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 750 mg/m\^2 intravenous (IV), Day 1 of each 21-day cycle, 6 cycles.
Study NCT01414855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: 50 mg/m\^2 IV, Day 1 of each 21-cycle, 6 cycles.
Study NCT01414855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: 100 mg/day, Days 1 through 5 of each 21-day cycle, 6 cycles.
Study NCT01414855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine
Description: 1.4 mg/m\^2 IV, Day 1 of each 21-day cycle, 6 cycles.
Study NCT00032110 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00032110 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00901394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B12-Folic Acid, nitrous oxide
Description: IV vitamin B12 (cyanocobalamin) 1 mg, single administration over 30 min.~IV folic acid, 5 mg, single administration over 30 min.~Both diluted in 250 ml normal saline.
Study NCT00901394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrous oxide (NO) and placebo
Description: 60% nitrous oxide anesthesia plus saline
Study NCT00901394 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrous oxide (NO) and placebo
Description: 60% nitrous oxide anesthesia plus saline
Study NCT00901394 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study NCT00901394 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Saline
Study NCT00901394 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: oxygen nitrogen
Description: 60% air and oxygen mix.
Study NCT02463331 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine diphosphate
Description: One pill of chloroquine diphosphate per day until the end of the study
Study NCT02463331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Prednisone 5-15 mg/day until the end of the study
Study NCT02463331 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Description: Prednisone 5-15 mg/day until the end of the study
Study NCT02463331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azathioprine
Description: azathioprine 1-2mg/Kg/day until the end of the study
Study NCT00561301 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: GemDOx
Description: gemcitabine oxliplatin
Study NCT01620658 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 0.5mm XPF cap
Description: Interventionalist wear a XPF 0.5mm lead equivalent cap during fluoroscopy guided interventions.~XPF is a trademark of BloXR (Salt lake City, UT) for a new bi-layer (Barium/Bismuth) radiation attenuation material.
Study NCT03559413 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Individual peptide vaccination with adjuvant GM-CSF and Imiquimod
Description: Intradermal injection of a cocktail of 3-5 individual HLA-binding peptides. Subcutaneous injection of adjuvant GM-CSF at vaccination site. Topical administration of Imiquimod at vaccination site.
Study NCT06683157 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: not drug
Description: Patients presenting with symptomatic ICVT will be examined by CCUS for both legs. Inclusion/exclusion criteria will be checked. No anticoagulation therapy is given. Compression stockings at the calf length will be prescribed for 30 days.~CCUS will be repeated on day 5±2, day 10±2, and day 30±4. If the ICVT has propagated into the trifurcation area, the popliteal vein, or into more proximal veins therapy will be implemented according to current guidelines for proximal DVT. If no propagation to proximal veins has occurred anticoagulation will be withheld further on.
Study NCT03546920 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ALIGN Intervention Phase
Description: Communication: The PCSW will follow this structured process to improve and facilitate communication for intervention patients. 1. Attend routine weekly facility-led rounds/meetings reviewing patients, their needs and attend discharge planning conference; 2. Visit with patient and caregiver after the discharge planning conference to ensure understanding of the plan of care; 3. Ensure all appropriate community programs (home health, community palliative care) have made contact and established care, assess the transition, and revisit domains from the initial assessment; 4. Suggest questions that need to be asked of community providers. Throughout the intervention, the PCSW will communicate updates from the visits to all involved providers.~Visits will also focus on increasing goal alignment with the objective that all participants have a ROLT score that is most aligned. Visits will also explore goals of care; this includes completion or review of advance directives.
Study NCT03624686 — intervention group
Intervention type: OTHER
Intervention: peripheral blood
Description: draw peripheral blood
Study NCT01620658 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 0.3mm XPF cap
Description: Interventionalist wear a XPF 0.3mm lead equivalent cap during fluoroscopy guided interventions.~XPF is a trademark of BloXR (Salt lake City, UT) for a new bi-layer (Barium/Bismuth) radiation attenuation material.
Study NCT01620658 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard cap
Description: Interventionalist wear a standard fabric cap during fluoroscopy guided interventions.
Study NCT02310724 — intervention group
Intervention type: OTHER
Intervention: TODAY cohort
Description: This protocol is observation only and involves no intervention, care, treatment, or management.
Study NCT05999058 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dacryoendoscopic-assisted laser dacryoplasty with silicone intubation
Description: The dacryoendoscopy was inserted into the lacrimal duct through the upper or lower lacrimal punctum. When the dacryoendoscopy reached the postsaccal obstruction, laser dacryoplasty (FOX diode laser, A.R.C. Laser, Nürnberg, Germany) was performed by widening the stenotic or obstructed section. After removing the dacryoendoscopy, a silicone tube inserted into lacrimal passage. Double bicanalicular silicone intubation was performed as previously described.
Study NCT01524224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2495655
Description: administered intravenously
Study NCT03220932 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cytoreductive surgery combined with HIPEC
Description: Cytoreductive surgery combined with HIPEC (Cisplatin 70 mg/m2).
Study NCT03220932 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy and bevacizumab (CT-BEV)
Description: Chemotherapy and bevacizumab (CT-BEV) 15 mg/kg once every 3 weeks from enrollment until disease progression (RECIST 1.1)
Study NCT04528017 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Verofilcon A contact lenses
Description: Spherical soft contact lenses for daily disposable wear
Study NCT04528017 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Somofilcon A contact lenses
Description: Spherical soft contact lenses for daily disposable wear
Study NCT02930382 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baroreflex assessment
Study NCT01175265 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: respiratory biofeedback
Description: In order to train effortless diaphragmatic breathing techniques the biofeedback loop starts at the sensor that measures the patient's breathing rhythm at both umbilical and abdominal level. The sensor is connected to an amplifier that converts the electrical impulses into acoustical and visual outputs. Patients were encouraged to regulate their breathing patterns at a 10-20% slower respiration rate resulting in increased tidal volumes. Furthermore, the patients were encouraged to reduce dynamic hyperinflation by completing the expiration prior to the initiation of the next breath while using pursed-lips breathing. Patients were trained to breath as comfortable as possible with predominant abdominal expansion during the inhalation and smooth abdominal contraction during exhalation.
Study NCT01794312 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: T4020
Study NCT01794312 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Study NCT03293849 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Navigation
Description: The patient navigator will discuss the results and supportive care recommended interventions of the multidisciplinary team with the patient. Those interventions which are accepted by patient are initiated when possible, and referrals are made as planned. The study patient navigator will review advance directive planning with those patients who are candidates to complete an advanced directive under Mexican law, and will facilitate the resources to complete the advance directive.
Study NCT01736072 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Laparoscopic Surgery
Description: The research subjects will be randomized to Standard Laparoscopic Surgical procedure to resect their Rectal Cancer.
Study NCT03923829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc Sulfate
Description: systemic administration of Zinc sulfate with scaling and root planing
Study NCT03923829 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: scaling and root planing
Description: scaling and root planing
Study NCT02960308 — intervention group
Intervention type: RADIATION
Intervention: Computed Tomography Perfusion Imaging
Description: Undergo WNCTP scan
Study NCT01736072 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Robotic Assisted Laparoscopic Surgery
Description: The research subjects will be randomized Robotic Assisted Laparoscopic Surgical procedure to resect their Rectal Cancer.
Study NCT04851314 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ICU certified ventilator
Description: Examine anesthetic consumption rates
Study NCT03694691 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Liver Biopsy
Description: For measurement of tissue co-factor levels, we will take needle biopsies of transplanted livers immediately after procurement, immediately prior to implantation (at the end of preservation), 30 minutes after portal vein reperfusion, and 30 minutes after hepatic artery reperfusion. For those livers that have more than 60 minutes between portal vein and hepatic artery reperfusion, an additional biopsy will be performed at 60 minutes after portal vein reperfusion. Post-procurement biopsies will be collected regardless of where the liver was obtained.
Study NCT00670046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valproic acid
Description: given orally
Study NCT00670046 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: standard of care follow-up
Description: participant follow the standard of care for patient with metastatic prostate cancer
Study NCT03807908 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tape
Description: The patient will be placed into maximal flexion of the lumbar spine prior to the tape being applied. The vertical strips will be applied on either side of spine, on the erector muscle group; from the lower PSIS with and end around the twelfth rib. The third strip of tape will be applied horizontally to superior to the posterior superior iliac spines (PSIS) and extend over the 2 vertical strips of tape. The tape will be gently rubbed to activate the adhesive.~Five to 7 days later, one of the investigators will follow up with the subjects over the phone and administer a questionnaire that will assess their experience with the tape as well as the outcome measures (numeric rating scale and Oswestry Disability Index).
Study NCT03807908 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Tape
Description: One strip of tape will be applied horizontally to the thoracolumbar junction (at the level of the lower rib cage over the T12-L1 spinous processes) with no tape-tension. The tape will be gently rubbed to activate the adhesive.~Five to 7 days later, one of the investigators will follow up with the subjects over the phone and administer a questionnaire that will assess their experience with the tape as well as the outcome measures (numeric rating scale and Oswestry Disability Index).
Study NCT01771484 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: External automated abdominal binder
Description: Participants will wear the abdominal compression binder on day 4 or 5 of the study diet. Seated and standing vitals will be collected before and during application of binder.
Study NCT01988935 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure
Description: Weekly psychotherapy sessions x 12 weeks, focused on gradually confronting distressing trauma-related memories and reminders.
Study NCT00325949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended release hydrocodone and acetaminophen (Vicodin CR)
Description: 2 tablets BID
Study NCT00325949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydrocodone/acetaminophen extended release (Vicodin CR)
Description: 1 tablet BID
Study NCT00325949 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 2 tablets BID
Study NCT02274766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADS-5102
Description: Oral capsules to be administered once nightly at bedtime, for 13 weeks.